Monoclonal Gammopathy of Uncertain Significance (MGUS) is an increasingly recognised incidental finding in general practice, particularly in the context of routine blood tests in older patients. While MGUS itself is often asymptomatic, it carries a risk of progression to more serious plasma cell disorders, including multiple myeloma. GPs play a critical role in the early identification, risk assessment, monitoring, and timely referral of patients with MGUS. This session will present the updated statewide guidance on the investigation and monitoring of paraproteins and MGUS, with a focus on when specialist referral is required. The webinar aims to equip GPs with practical, evidence-based knowledge to support confident decision-making in the assessment and management of these patients in primary care.
This event is RACGP & ACCRM approved for 1.5 Hours of Education Activities
Learning Outcomes:
- Recognise the clinical significance of paraproteins and MGUS as incidental findings in general practice.
- Apply the latest statewide guidance to appropriately investigate and monitor patients with MGUS in the primary care setting.
- Identify red flags and high-risk features that indicate need for referral to haematology or secondary care.
- Interpret common laboratory investigations/findings related to monoclonal proteins in the context of patient age, comorbidities, and clinical presentation.